Cat. No. | Product name | CAS No. |
DCC5597 |
Zbh-1205
Novel camptothecin derivative, revealing potent antitumor activities mainly through cell apoptosis pathway, being more effective than CPT-11 and SN38 at inhibiting topoismerase-1 |
|
DCC5598 |
Zd1611
Endothelin Receptor Antagonist |
186497-38-1 |
DCC5599 |
Zd2138
Potent, orally active inhibitor of 5-lipoxygenase (5-LO) |
140841-32-3 |
DCC5600 |
Zd6126
Vascular targeting agent (VTA) |
219923-05-4 |
DCC5601 |
zd6169
Potassium channel opener |
147696-46-6 |
DCC5602 |
Zdhhc Substrate Peptide
ZDHHC (zinc finger Asp-His-His-Cys) substrate peptide, a 15-mer peptide sequence from KRas4a plus two tryptophan residues |
|
DCC5603 |
Zdlt-1
Novel potent HDAC inhibitor with IC50 values for class I HDACs 1, 2, and 3 below 4 nM, and IC50 for HDAC6 at 6 nM. |
|
DCC5604 |
Z-don-val-pro-leu-ome
Site specific inhibitor of tissue transglutaminase |
|
DCC5605 |
Zdwx-25
Novel daul inhibitor of GSK-3β (IC 50 = 71 nM) and DYRK1A (IC 50 = 103 nM) with good blood-brain barrier penetrability, inhibiting hyperphosphorylation of tau protein in okadaic acid (OKA)-induced SH-SY5Y cells |
|
DCC5606 |
Zfh7116
Novel inhibitor of pro-HGF activation |
|
DCC5607 |
Zg-2033
Novel Potent and Orally Bioavailable Hypoxia-Inducible Factor 2α (HIF-2α) Agonist |
|
DCC5608 |
Z-ggr-amc
Fluorogenic peptide substrate for a direct fluorometric assay of urokinase, tissue-type plasminogen activator, trypsin and thrombin |
66216-78-2 |
DCC5609 |
Ziconotide
Atypical analgesic agent for the amelioration of severe and chronic pain |
107452-89-1 |
DCC5610 |
Zilpaterol
Growth promotant, acting as a ß-AR (ß-Adrenergic) agonist |
119520-05-7 |
DCC5611 |
Zinc00723145
The first nonpeptidic inhibitor of ovarian cancer cells growth targeting human thymidylate synthase (hTS) |
352348-99-3 |
DCC5612 |
Zinc01765622
Novel antagonist for mLST8 |
61601-94-3 |
DCC5613 |
Zinc03838680
Potent VEGFR-2 inhibitor |
|
DCC5614 |
Zinc04085549
Novel blocker of AKT1-FAK interaction, reducing the stimulation of FAK phosphorylation in response to extracellular pressure in human SW620 colon cancer cells without affecting basal FAK phosphorylation |
383147-88-4 |
DCC5615 |
Zinc04177596
Novel Nef Protein Inhibitor; Anti-HIV |
364052-84-6 |
DCC5616 |
Zinc04502991
Novel TNF-α inhibitor |
878427-47-5 |
DCC5617 |
Zinc04515726
Novel effective immune checkpoint inhibitor (ICI) against the suppression of T-cell activation, proliferation, and tumor cell eradication. |
|
DCC5618 |
Zinc04574788
Novel potent small molecule lligand of miR-21, binding to the major groove of miR-21 hairpin conformation |
|
DCC5619 |
Zinc05848961
Novel TNF-α inhibitor |
|
DCC5620 |
Zinc06472206
Potent and selective agonist of peroxisome proliferator activated receptors-α (PPAR-α) |
313962-58-2 |
DCC5621 |
Zinc08438472
Potent and selective agonist of peroxisome proliferator activated receptors-α (PPAR-α) |
443872-20-6 |
DCC5622 |
Zinc08790006
Novel SIRT1 inhibitor |
864751-93-9 |
DCC5623 |
Zinc08792229
Novel SIRT1 inhibitor |
904514-73-4 |
DCC5624 |
Zinc08792355
Novel SIRT1 inhibitor |
904513-52-6 |
DCC5625 |
Zinc08985213
Novel effective immune check point inhibitor (ICI) against the suppression of T-cell activation, proliferation, and tumor cell eradication. |
|
DCC5626 |
Zinc09410451
Potent Ebolavirus (EBOV) Inhibitor |
1093065-66-7 |
DCC5627 |
Zinc12909780
Novel dose-dependent inhibitor of TNF-α-induced NF-κB activation |
|
DCC5628 |
Zinc17043486
Novel CDK6 inhibitor |
|
DCC5629 |
Zinc17167211
Potent and selective agonist of peroxisome proliferator activated receptors-α (PPAR-α) |
592539-21-4 |
DCC5630 |
Zinc20531199
Novel EGFR triple mutant T790M/C797S allosteric inhibitor |
|
DCC5631 |
Zinc27905174
Novel GDNF Family Receptor Agonist |
|
DCC5632 |
Zinc32540717
Potent Ebolavirus (EBOV) Inhibitor |
1010869-76-7 |
DCC5633 |
Zinc36617540
Novel Nef Protein Inhibitor; Anti-HIV |
1174905-91-9 |
DCC5634 |
Zinc4085554
Novel blocker of AKT1-FAK interaction, reducing the stimulation of FAK phosphorylation in response to extracellular pressure in human SW620 colon cancer cells without affecting basal FAK phosphorylation |
383147-92-0 |
DCC5635 |
Zinc50166190
Novel Zika virus RNA polymerase inhibitor |
1455388-54-1 |
DCC5636 |
Zinc63908257
Novel CtpF inhibitor, inhibiting Ca -dependent ATPase activity in Mtb membrane vesicles |
|
DCC5637 |
Zinc64700951
Novel gp120 of HIV-1 Antagonist |
|
DCC5638 |
Zinc65022200
Novel potent and specific inhibitor of the UNC119-Src interaction, binding to UNC119 in cells, and inducing redistribution of Src to endomembranes and reduction of activating Src autophosphorylation on Y419 |
|
DCC5639 |
Zinc69811181
Novel ASCT2 inhibitor |
|
DCC5640 |
Zinpyr-1
Cell-permeable fluorometric zinc sensor |
288574-78-7 |
DCC5641 |
Zk187638
Non-competitive AMPA receptor antagonist |
397298-63-4 |
DCC5642 |
Zk230211
Type III progesterone receptor antagonist with enhanced antiproliferative properties |
211254-73-8 |
DCC5643 |
Zk-304709
Novel oral multitarget tumour growth inhibitor |
1010440-84-2 |
DCC5644 |
Zk-806450
Novel potent inhibitor of factor Xa (FXa) |
|
DCC5645 |
Zl006-05
Novel dual mordulator of nNOS-PSD-95 interaction and GABA A receptor |
|
DCC5646 |
Zl0513
Novel potent and selective BRD4 bromodomain 1 (BD1) inhibitor |
2230496-92-9 |
DCC5647 |
Zl0516
Novel potent and selective BRD4 bromodomain 1 (BD1) inhibitor |
2230496-93-0 |
DCC5648 |
Zl3138
Novel β-catenin/B-cell lymphoma 9 (BCL9) inhibitor, disrupting the β-catenin/BCL9 protein-protein interaction (PPI) with a Ki of 0.96 μM and without affecting the β-catenin/E-cadherin interaction in living cells, displaying good selectivity for β-catenin/ |
|
DCC5649 |
Zld10a
Novel potent and highly selective inhibitor of wild-type and mutant versions of EZH2 |
1782064-91-8 |
DCC5650 |
Zm-181037
ATP-sensitive potassium channel-blocker; Eukalemic diuretic |
138779-29-0 |
DCC5651 |
zm-189154
Non-steroidal pure antioestrogen |
101908-22-9 |
DCC5652 |
zm-230487
5-Lipoxygenase (5-LO) inhibitor |
155944-23-3 |
DCC5653 |
Zm-244085
K-Channel opener (PCO) activating predominantly KATP channels in vitro to relax bladder detrusors |
149398-59-4 |
DCC5654 |
zm-253270
Selective nonpeptide, NK-2 receptor (NK-2R) antagonist |
169340-04-9 |
DCC5655 |
Zm-260384
Potassium channel opener |
161229-62-5 |
DCC5656 |
Zm39923 Hydrochloride
Potent, selective inhibitor of Janus tyrosine kinase 3 (JAK3) |
58753-54-1 |
DCC5657 |
Zn-htsm
Novel antidiabetic agent for the treatment of type 2 diabetes mellitus (DM) |
|
DCC5658 |
Zofenoprilat
Inducer of functional angiogenesis through increased H 2 S availability |
75176-37-3 |
DCC5659 |
Zolantidine Dimaleate
Potent, selective, and brain penetrating H2 receptor antagonist |
104076-39-3 |
DCC5660 |
Zoledronate Disodium
Inhibitor of osteoclastogenesis and macrophage recruitment, decreasing bone turnover and stabilizing the bone matrix, exhibiting diverse anti-tumor effects in osteosarcoma |
131654-46-1 |
DCC5661 |
Zolimidine
Gastroprotective agent for the treatment of peptic ulcer |
1222-57-7 |
DCC5662 |
Zp1-12cl
Novel zinc sensor with a chloroalkane linker, reacting specifically with the engineered protein HaloTag, binding zinc ions with a threefold fluorescence enhancement |
|
DCC5663 |
Ztb23(r)
The first potent and selective Mycobacterium tuberculosis Zmp1 inhibitor |
306324-21-0 |
DCC5664 |
Ztz240
Novel potentiator of KCNQ2 potassium channels |
325457-98-5 |
DCC5665 |
Zu-4280011
Novel COX-2 inhibitor |
1001770-63-3 |
DCC5666 |
Zuclopenthixol Dihydrochloride
Antagonist of D1 and D2 dopamine receptors. |
58045-23-1 |
DCC5667 |
Z-wehd-fmk
Potent, cell-permeable and irreversible caspase-1/5 inhibitor |
210345-00-9 |
DCC5668 |
Zwittermicin A
Natural antibiotic, having diverse biological activities including broad-spectrum antibiosis against Bacteria and lower Eukarya, plant disease suppression, and enhancement of the insecticidal activity of Bacillus thuringiensis toxin against lepidopteran l |
155547-95-8 |
DCC5669 |
Zwm026
Novel multi-target inhibitor, harboring selectivity of inhibiting EGFR T790M sparing wild-type EGFR |
|
DCC5670 |
Zxh-1-161
Featured
Novel Selective Degrader of GSPT1 |
2407654-51-5 |
DCC5671 |
Zx-j-19j
Novel inhibitor of Cyclophilin J (CyPJ) PPIase, demonstrating remarkable inhibition of tumor cell growth, comparable to CsA but much stronger than 5-fluorouracil |
1352576-02-3 |
DCC5672 |
Zx-j-19l
Novel inhibitor of Cyclophilin J (CyPJ) PPIase, demonstrating remarkable inhibition of tumor cell growth, comparable to CsA but much stronger than 5-fluorouracil |
1346754-06-0 |
DCC5673 |
Zxx2-77
Cyclooxygenase-1 inhibitor |
304913-22-2 |
DCC5674 |
Zydpla1
Novel next generation orally active DPP-4 inhibitor to treat Type 2 Diabetes |
1263402-76-1 |
DCC5675 |
Zyj-25e
Novel histone deacetylase inhibitor (HDACi) with potent oral antitumor activities |
1287261-04-4 |
DCC5676 |
Zyj-34c
Novel histone deacetylase inhibitor (HDACi) with potent oral antitumor activities |
1314556-93-8 |
DCC5677 |
Zyj-34v
Oral active histone deacetylase inhibitor with potent antitumor activity |
1450662-32-4 |
DCC5678 |
Zyz-803
Novel slow H2S-NO-releasing hybrid, attenuating cardiac dysfunction after heart failure |
2088043-51-8 |
DC65717 |
DPPE
Featured
DPPE is a derivative of phosphatidylethanolamine with (16:0) palmitoyl acyl chains |
923-61-5 |
DC65720 | Bis(linoleyl) ketone Featured | 1169768-30-2 |
DC65721 | 1,2(R)-Dioleyloxy-sn-giycero-3-phosphocholine Featured | 145849-25-7 |
DC65722 | 1,2-Dioleyloxy-sn-giycero-3-phosphocholine Featured | 1068-79-0 |
DC65723 |
1-Palmitoyl-sn-glycero-3-phosphocholine
Featured
1-Palmitoyl-sn-glycero-3-phosphocholine is an abundant gonadal LPC (lysophosphatidylcholine). |
17364-16-8 |
DC65725 |
1-Palmitoyl-2-oleoyl-sn-glycero-3-PC
Featured
1-Palmitoyl-2-oleoyl-sn-glycero-3-PC (POPC), a phospholipid, is a major component of biological membranes. 1-Palmitoyl-2-oleoyl-sn-glycero-3-PC is used for the preparation of liposomes and studying the properties of lipid bilayers. |
26853-31-6 |
DC65726 | DPPE-cap-Biotine Featured | 384835-52-3 |
DC65727 |
DMPG
Featured
DMPG is a phospholipid containing the saturated long-chain (14:0) myristic acid. |
200880-40-6 |
DC65728 |
DSPA
Featured
DSPA is a form of phosphatidic acid (PA) containing a phosphatidic acid head group and 18:0 fatty acids |
108321-18-2 |
DC65729 |
DOPG-Na
Featured
DOPG-Na is a phospholipid containing the long-chain (18:1) fatty acid oleic acid inserted at the sn-1 and sn-2 positions. It can be used in the generation of micelles, liposomes, and other artificial membranes. DOPG is an anionic phospholipid derivative. The negatively charged liposomes prepared with DOPG has been found to possess the best loading capacity and encapsulation rate for Peptide Nucleic Acid (PNA) oligomers. |
67254-28-8 |
DC65730 |
DPhPC
Featured
DPhPC is a phospholipid used to synthesize bilayer vesicles. DPhPC bilayers do not permit ions to leak in the absence of a pore/ion channel, which can be used for studies on channel proteins. |
207131-40-6 |
DC65731 |
DPPA
Featured
DPPA is a form of phosphatidic acid (PA). |
169051-60-9 |
DC65739 |
18:0-18:2 PE
Featured
18:0-18:2 PE is a lipid for agents delivering. 18:0-18:2 PE is mainly composed of unsaturated fatty acids. 18:0-18:2 is considered important precursors of important odorants (IOs) in Eriocheir sinensis. |
7266-53-7 |
DC65742 | (s)-1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine Featured | 71357-99-8 |
DC65745 |
POPE
Featured
POPE is a phospholipid, and can be used for drug delivery. |
26662-94-2 |
DC65753 |
DOTAP Mesylate
Featured
DOTAP mesylate is a biochemical reagent that can be used as a biological material or organic compound for life science related research. |
252769-92-9 |
DC65754 | DSG Featured | 1429-59-0 |
DC65757 | AOP Featured | 156311-85-2 |
DC65758 | Methoxypoly(ethylene glycol)propionitrile(mPEG-CN) Featured | |
DC65759 | Methoxypoly(ethylene glycol)Giycerol(mPEG-GLC) Featured | |
DC65760 | Methoxypoly(ethylene glycol)Epoxide(mPEG-epoxide) Featured | |
DC65761 | DMG-mPEG2000(酯型) Featured | |
DC65762 | Polyethylene glycol[PEG]dimyristoyl glycerol Epoxide Featured | |
DC65763 | MPEG-GLC Featured | |
DC65765 | mPEG2000-CH2CH2CN Featured | |
DC65766 | mPEG2000-NPC Featured | |
DC65770 | DMPE-mPEG2000(NA盐) Featured | 384835-59-0 |
DC65771 | DMG-mPEG5000 Featured | |
DC65777 |
DLPA
Featured
DLPA is a phosphatidic acid (PA) containing the medium-chain (12:0) lauric acid. |
108321-06-8 |
DC65778 | PLinPE Featured | 26662-95-3 |
DC65779 | PLPA Featured | 322647-59-6 |
DC65780 |
DLPE
Featured
DLPE is a derivative of phosphatidylethanolamine with lauric acid (12:0) acyl chains. |
59752-57-7 |
DC65781 |
DPyPE
Featured
DPyPE is a phosphatidylethanolamine lipid composed of polyisoprene alkyl chains. DPyPE is a co-lipid forvaxfectin mixed with GAP-DMORIE in a 1:1 ratio. |
201036-16-0 |
DC65784 | SOPA-NA Featured | 384833-24-3 |
DC65785 | 18:0 Diether PC Featured | 1188-85-8 |
DC65786 |
mPEG2000-DSPE
Featured
mPEG2000-DSPE is used in COVID 19 mRNA vaccines. It is a PEGylated derivative of 1,2-distearoyl-sn-glycero-3-PE . Formulations containing DSPE-MPEG(2000) have been used to prepare liposomes with long circulation time for the delivery of anticancer and antimalarial agents.. mPEG2000-DSPE has also been widely used as hydrophilic surface modifying agent for a variety types of hydrophobic nanoparticles, including recently reported lipid nanoparticle mRNA vaccines. |
247925-28-6 |
DC65787 | DOP-DEDA Featured | 2247753-10-0 |
DC65788 | DHSM Featured | 54353-31-0 |
DC65791 |
DPPG sodium
Featured
DPPG sodium is a biochemical reagent that can be used as a biological material or organic compound for life science related research. |
67232-81-9 |
DC65796 | Tritridecanoin Standard Featured | 26536-12-9 |
DC65797 |
Diheptanoyllecithin
Featured
Diheptanoyllecithin is a non-hydrolyzable analog. |
39036-04-9 |
DC60546 |
514O6,10
Featured
514O6,10 is an ionizable lipidoid. 514O6,10 formulated LNPs facilitate mRNA delivery to the pancreas. |
|
DC60554 |
Lipid 20b
Featured
Lipid 20b is an ionizable lipid containing a thiophene moiety (Thio-lipid) for mRNA delivery. Lipid 20b enables LNPs to transfect the liver and spleen. Lipid 20b is potent in mRNA delivery to the retina with no acute toxicity. |
|
DC60555 |
C14-O2
Featured
C14-O2 is an oxidized lipid for mRNA delivery. C14-O2-LNP is capable of potent and selective delivery of mRNA to blood monocytes. C14-O2 LNP is used to deliver a functional CD19-CAR mRNA and is shown to engineer functional CAR monocytes directly in situ. |
2639634-77-6 |
DC60556 |
Lipid 29d
Featured
Lipid 29d is an ionizable lipid containing a thiophene moiety (Thio-lipid) for mRNA delivery. Lipid 29d enables LNPs to transfect the lung and spleen. |
|
DC65849 |
A1-28
Featured
A1-28 is a disulfide bond-containing ionizable cationic lipid.1 It has been used in the generation of lipid nanoparticles (LNPs) for the delivery of CRISPR complementary single-guide RNA (sgRNA) and Cas9 mRNA for genome editing in vitro. |
|
DC65850 |
VL422
Featured
VL422 is an ionizable cationic lipid.1 It has been used in the generation of lipid nanoparticles (LNPs) for the delivery of CRISPR complementary single-guide RNA (sgRNA) and Cas9 mRNA for gene editing in vitro and in vivo. LNPs containing VL422 and encapsulating Cas9 mRNA and sgRNA targeting the gene encoding angiopoietin-related protein 3 (ANGPTL3), a protein whose loss-of-function decreases LDL, HDL, and cholesterol plasma levels, induce a deletion in a premature stop codon in ANGPTL3 in the livers of cynomolgus monkeys. |
2765519-47-7 |
DC65851 |
CL15F6
Featured
CL15F6 is an ionizable cationic lipid (pKa = 6.75).1 It has been used in the formation of lipid nanoparticles (LNPs) for the delivery of mRNA and polymer-lipid hybrid nanoparticles for the delivery of plasmid DNA in vitro.1,2 |
2766493-40-5 |
DC65852 |
C3-K2-E14
Featured
C3-K2-E14 is an ionizable cationic lipid (pKa = 5.5).1 It has been used in the generation of lipid nanoparticles (LNPs) for the delivery of mRNA or siRNA in vitro and in vivo. LNPs containing C3-K2-E14 and encapsulating siRNA targeting the gene encoding colony-stimulating factor 1 (Csf1) reduce the percentage of circulating Ly6Chi monocytes and increase the percentage of circulating Ly6Cint monocytes in mice. |
2933215-86-0 |
DC65853 |
(S)-C12-200
Featured
(S)-C12-200 is an ionizable cationic lipid (pKa = 7.12) and an isomer of C12-200 (Item No. 36699).1 It has been used in the formation of lipid nanoparticles (LNPs) for the delivery of mRNA in vivo. Intravenous administration of LNPs containing (S)-C12-200 and encapsulating mRNA encoding Cre recombinase increase the percentage of tdTomato+ hepatocytes, endothelial cells, and Kupffer cells in the livers of Ai14 mice greater than (R)-C12-200-containing and Cre mRNA-encapsulating LNPs. |
1226552-44-8 |
DC65854 |
PPPDA-O16B
Featured
PPPDA-O16B is a disulfide bond-containing ionizable cationic lipid that has been used in the generation of lipid nanoparticles (LNPs) for plasmid delivery in vitro and in vivo.1 LNPs containing PPPDA-O16B and encapsulating plasmids encoding Ras/Rap1-specific endopeptidase (RRSP) increase RRSP levels and decrease Ras levels in, and reduce the viability of, HeLa cervical cancer cells. LNPs containing PPPDA-O16B and encapsulating plasmids encoding RRSP selectively localize to tumors over the heart, liver, spleen, lungs, and kidneys, as well as decrease tumor volume without reducing body weight, in an HCT116 colorectal cancer mouse xenograft model. |
|
DC65856 |
Lipid C3
Featured
Lipid C3 is an ionizable cationic lipid (pKa = 5.05-5.671).1,2 It has been used in the formation of lipid nanoparticles (LNPs) for the delivery of mRNA in vitro and in vivo.1 Intracerebroventricular administration of LNPs containing lipid C3 and encapsulating mRNA encoding α-L-iduronidase (Idua) to neonates increase midbrain and hippocampal α-L-iduronidase enzyme activity and decrease forebrain, midbrain, and hippocampal glycosaminoglycan levels in an Idua-W392X mouse model of the lysosomal storage disorder mucopolysaccharidosis type I, also known as Hurler syndrome. Intracerebroventricular administration of LNPs containing lipid C3 and encapsulating an mRNA reporter to fetal macaques in utero increase brain GFP expression. |
2639634-93-6 |
DC65857 |
BAmP-O16B
Featured
BAmP-O16B is an ionizable cationic amino lipid that has been used in the generation of lipid nanoparticles (LNPs).1 LNPs containing BAmP-O16B and encapsulating NSA-inactivated RNase A reduce the viability of SiHa and HeLa cancer cells, but not non-cancerous NIH3T3 and HEK293T cells, upon intracellular reactivation of RNase A by glutathione (GSH). |
|
DC65858 |
Lipid OA2 (hydrochloride)
Featured
Lipid OA2 is an ionizable cationic lipid that has been used in the generation of single-component lipid nanoparticles (LNPs) for the delivery of siRNA.1 LNPs containing lipid OA2 and siRNA targeting the gene encoding suppressor of cytokine signaling 1 (Socs1) decrease Socs1 expression by approximately 50% in isolated mouse bone marrow dendritic cells (BMDCs). Vaccination with ovalbumin-induced isolated mouse BMDCs transfected with LNPs composed of lipid OA2 and Socs1-targeting siRNA increases survival and decreases tumor volume in a B16-OVA murine melanoma model. |
|
DC72914 |
UE2343
UE2343 (UE-2343, Xanamem) is a potent, orally bioavailable, brain penetrant 11β-HSD1 inhibitor with IC50 of 24 nM in cell-free assays, with no activity for isozyme 11β-HSD2. |
1346013-80-6 |
DC72915 |
AM4085
AM4085 is a potent, orally bioavailable lectin domain of FmLH antagonist with IC50 of 0.19 uM. |
|
DC72916 |
BB2-50F
BB2-50F is a bactericidal inhibitor of M. tuberculosis with MIC value of 8 uM (H37Rv), inhibits succinate dehydrogenase and the F1Fo-ATP synthase. |
2226086-65-1 |
DC72917 |
BDM71339
BDM71339 is the first small molecule inhibitor of mycobacterial transcriptional regulator EthR, boosts ten times the activity of ethionamide in TB-infected macrophages at low nanomolar concentrations (EC50=72 nM) in vitro. |
2580938-64-1 |
DC72918 |
BDM88855 hydrochloride
BDM88855 Hcl is a novel allosteric efflux-pump inhibitor that potentiate antibiotic activity in E. coli through inhibition of its primary RND transporter, AcrAB-TolC. |
2892824-26-7 |
DC72919 |
BDM91288
BDM91288 is a pyridylpiperazine-based AcrB efflux pump inhibitor, potentiate the activity of a panel of antibiotics against K. pneumoniae. |
2892824-53-0 |
DC72920 |
BFA1
BFA1 is a specific small-molecule activator of Burkholderia FixLJ signaling pathway, inhibit the virulence of multiple pathogenic Burkholderia species. |
263563-30-0 |
DC72921 |
COE2-2hexyl
COE2-2hexyl is a broad-spectrum antibacterial conjugated oligoelectrolyte (COE), does not evoke bacterial resistance, inhibits methicillin-resistant S. aureus (MRSA, MT3302) with MIC of 1 ug/mL. |
2376953-07-8 |
DC72922 |
Cresomycin
Cresomycin (CRM) is a bridged macrobicyclic antibiotic via inhibiting bacterial ribosome, shows broad efficacy of CRM against clinical isolates of MDR Gram-negative pathogens differentiates the synthetic macrobicyclic class from traditional lincosamides. |
2999743-51-8 |
DC72923 |
CUO246
CUO246 (CUO-246) is a potent, selective bacterial DNA gyrase/topoisomerase IV inhibitor, CUO246 is active in vitro against a broad range of Gram-positive, fastidious Gram-negative, and atypical bacterial pathogens. |
2250037-27-3 |
DC72924 |
D66
D66 is a specific small molecule that disrupts S. Typhimurium membrane voltage without cell lysis, prevents S. Typhimurium survival in macrophages (IC50=6.0 uM) and inhibits bacterial growth under conditions that compromise the cell envelope. |
651005-35-5 |
DC72925 |
DS01750413
DS01750413 is a novel FtsZ inhibitor and new derivative of PC190723 (Cat. PC-47012), inhibits S. aureus FtsZ protein with IC50 of 2 mg/L, has an IC50 of 0.03 mg/L in cell elongation assay of B. subtilis. |
2881067-92-9 |
DC72926 |
EPM35
EPM35 (Efflux pump modulator 35) is a small molecule that bind AcrB (KD=0.29 uM), inhibit AcrAB-TolC and modulates bacterial efflux pump activity, reduces bacterial intracellular load. |
651006-73-4 |
DC72927 |
GSK030
GSK030 (GSK3212030A) is an antimalarial compound that targets blood-stage activity of the Plasmodium falciparum and Plasmodium vivax parasites. |
1954699-40-1 |
DC72928 |
GSK147
GSK147 (GSK-147) is an antimalarial compound that targets blood-stage activity of the Plasmodium falciparum and Plasmodium vivax parasites (Pf IC50=40 nM). |
|
DC72929 |
GSK692
GSK692 (GSK-692) is an antimalarial compound that targets blood-stage activity of the Plasmodium falciparum and Plasmodium vivax parasites (Pf IC50=10 nM). |
2095562-44-8 |
DC72930 |
HR3744
HR3744 is a selective small molecule inhibitor of S. aureus exoprotein expression regulator (SaeR) withEC50 of 10 uM in saeP1 promoter assays, reduces expression of hla and other virulence factors. |
359614-79-2 |
DC72931 |
HSGN-189
HSGN-189 is a potent lipoteichoic acid (LTA) biosynthesis inhibitor, exhibits potent antibacterial activity against both MRSA and VRE strains with MICs of 1 ug/mL. |
2378181-36-1 |
DC72932 |
IITR06144
IITR06144 is a novel nitrofuran and exhibits broad-spectrum bactericidal activity against most MDR bacteria (MIC, 0.5 mg/mL). |
89076-51-7 |
DC72933 |
JBD1
JBD1 is a small molecule compound that strongly inhibits biofilm formation of S. aureus, including methicillin-resistant strains, induces biofilm inhibition and metabolic remodeling through respiratory activation. |
577981-37-4 |
DC72934 |
JMV-7061
JMV7061 (JMV-7061) is a novel potent, selective bacterial metallo-β-lactamase (MBL) inhibitor, shows submicromolar activities against VIM-type enzymes and strong NDM-1 inhibition (Ki=10-30 nM). |
2419903-20-9 |
DC72935 |
JSF-2414
Featured
JSF-2414 (JSF2414) is a potent, small molecule GyrB/ParE dual binding inhibitor, simultaneously binds to ATP binding regions of DNA gyrase (GyrB) and topoisomerase (ParE) and displays potent in vitro activity against strains of MRSA, VRSA and VISA. |
1673581-19-5 |
DC72936 |
JSF-2659
JSF-2659 is the orally bioavailable, phosphate prodrug of JSF-2414, JSF-2659 (100 and 1 g/kg, p.o.) is highly efficacious in reducing microbial burdens in animal models of Neisseria gonorrhoeae vaginal infection as well as VRSA and C. difficile-induced co |
|
DC72937 |
JSF-3269
JSF-3269 is a small molecule antibacterial inhibitor against Enterococcus faecium with MIC of 1.9-3.8 uM and minimal bactericidal concentration (MBC) of 7.7-15 uM. |
|
DC72938 |
JSF-3285
JSF-3285 (JSF3285) is a potent small molecule inhibitor of the M. tuberculosis β-ketoacyl synthase KasA with Kd of 70.7 nM in MST assays, shows activity against H37Rv strain with MIC 0.2 uM. |
|
DC72939 |
KKL-55
KKL-55 is a specific small molecule inhibitor of bacterial trans-translation by binding to longation factor thermo-unstable (EF-Tu, Kd=2 uM), inhibits binding between EF-Tu and tmRNA but not between EF-Tu and tRNA, has broad-spectrum antibiotic activity. |
639048-45-6 |
DC72940 |
KSK67
KSK67 is a potent small molecule inhibitor of bacterial transcriptional activator PrfA with IC50 of 67 nM, reduces virulence factor expression in L. monocytogene. |
1638100-60-3 |
DC72941 |
LPC-233
LPC-233 (LPC233) is a highly potent and specific inhibitor of UDP-3-O-(R-3-hydroxyacyl)-N-acetylglucosamine deacetylase LpxC (Ki=8.9 pM), specifically inhibits lipid A synthesis and displays outstanding antibiotic activities. |
2142075-09-8 |
DC72942 |
MD-124
MD-124 is a potent antibiotic adjuvant against Gram-negative bacteria, sensitizes various Gram-negative bacterial species and strains, including multidrug resistant pathogens, toward existing antibiotics. |
2402826-89-3 |
DC72943 |
MMV1091186
MMV1091186 (MMV 1091186) is an antimalarial compound that inhibit P. falciparum cytoplasmic isoleucyl tRNA synthetase (cIRS) with IC50 of 0.87 uM. |
1043049-81-5 |
DC72944 |
MMV652103
MMV652103 is an antimalarial imidazopyridazine compound, exerts potent and selective cytotoxicity in ER+ breast cancer cells, potently inhibits the oncogenic PI4KB and PIK3C2G lipid kinases with IC50 of 1.7 and 0.085 uM, respectively. |
1580453-63-9 |
DC72945 |
MSU-43085
MSU-43085 is a potent, orally bioavailable inhibitor of Mycobacterium tuberculosis (Mtb, EC50=120 nM) and M. abscessus survival, targets MmpL3. |
2810846-51-4 |
DC72946 |
ND-011992
ND-011992 is a cytochrome bd oxidase (Cyt-bd) inhibitor, inhibits Mycobacterium tuberculosis respiratory complex I with IC50 of 0.12 uM, targets respiratory complex I and bo3 oxidase in addition to bd-I and bd-II oxidases. |
2446880-46-0 |
DC72947 |
NSC116565
NSC116565 is a potent, time-dependent inhibitor of Mycobacterium tuberculosis (M.tb) ketol-acid reductoisomerase (KARI) with Ki of 95.4 nM. |
18903-23-6 |
DC72948 |
NTB-3119
NTB-3119 (NTB3119) is a novel benzothiopyranone derivative and anti-tuberculosis agent with potent in vitro activity against both drug-susceptible and drug-resistant tuberculosis clinical strains. |
2252473-48-4 |
DC72949 |
OTB-658
OTB-658 (OTB658) is a novel oxazolidinone anti-tuberculosis agent, shows potent antibacterial activity against Mycobacterium tuberculosis, especially multi-drug resistant tuberculosis (MDR-TB) in vitro and in vivo. |
2245791-50-6 |
DC72950 |
PKZ18-22
PKZ18-22 is a potency improved analog of PKZ18, inhibitiong tRNA-regulated gene expression of gram-positive bacteria, shows MIC value of 8 ug/mL against S. aureus. |
361366-77-0 |
DC72951 |
SAV13
SAV13 is a selective small molecule inhibitor of S. aureus exoprotein expression regulator (SaeR) withEC50 of 1.06 uM in luciferase assays, reduces expression of hla and other virulence factors. |
423748-49-6 |
DC72952 |
Savirin
Savirin (S. aureus virulence inhibitor) is a small molecule inhibitor inhibiting agr quorum sensing in S. aureus by blocking the transcriptional function of AgrA. |
2163006-04-8 |
DC72953 |
SF235
SF235 is a small-molecule inhibitor of macrophage infectivity potentiator (Mip) protein with IC50 and Ki 0.42 and 0.29 uM against B. pseudomallei Mip (BpMip) peptidyl-prolyl cis/trans isomerase (PPIase) activity, reduce B. pseudomallei virulence in vitro. |
2010156-60-0 |
DC72954 |
SK-017154-O
SK-017154-O is a specific and noncompetitive inhibitor of PelA, specifically inhibits PelA esterase activity with IC50 of 11 uM, inhibits Pel-dependent PA14 biofilms with IC50 of 1.8 uM. |
133978-91-3 |
DC72955 |
SMARt751
SMARt751 is a small molecule that interacts with the transcriptional regulator VirS of M. tuberculosis, up-regulates expression of the mymA operon, reverses resistance to ethionamide both in vitro and in vivo. |
1616370-52-5 |
DC72956 |
SMT-738
SMT-738 is a small-molecule inhibitor of bacterial lipoprotein transport complex (LolCDE), shows potent and highly selective antimicrobial activity. |
2862851-15-6 |
DC72957 |
TBAJ-5307
TBAJ-5307 is a broad spectrum anti-non-tuberculous mycobacteria (NTM) inhibitor targeting FO-domain of F1FO-ATP synthase, shows MIC50 of 4.5 nM and 6 nM against the Mab subsp. abscessus smooth strain and rough strain respectively. |
2583850-72-8 |
DC72958 |
TBI-166
TBI-166 is a potential next-generation antituberculosis riminophenazine with activity against Mycobacterium tuberculosis (0.063 μg/ml). |
2377282-66-9 |
DC72959 |
TPP8
TPP8 is a small molecule antibacterial inhibiting the ATPase of DNA gyrase with IC50 of 0.3 uM, binds and inhibits the ATPase domain of the gyrase B subunit, shows activity against M. abscessus strains with MIC of 0.04-0.2 uM. |
1581683-17-1 |
DC72960 |
TXA707
TXA707 is the active metabolite of TXA709 and bacterial protein FtsZ inhibitor, maintains potent activity against S. aureus strains (e.g., MRSA, VRSA, DNSSA, and LNSSA) that are resistant to current SOC antibiotics. |
1609670-89-4 |
DC72961 |
TXA709
TXA709 is a prodrug of FtsZ-targeting benzamide compound (TXA707) with enhanced metabolic stability, demonstrates improved pharmacokinetic properties, and superior in vivo antistaphylococcal efficacy (both oral and intravenous) relative to previously iden |
1609670-80-5 |
DC72962 |
TXY436
TXY436 is an N-Mannich base derivative and FtsZ-directed prodrug of PC190723, TXY436 is effective against S. aureus can also target Gram-negative bacteria, such as Escherichia coli. |
1459695-13-6 |
DC72963 |
TXY541
TXY541 is a 1-methylpiperidine-4-carboxamide prodrug of PC190723 and bacterial protein FtsZ inhibitor, TXY541 is efficacious in vivo in mouse models of systemic infection with both methicillin-sensitive and methicillin-resistant S. aureus. |
1499168-63-6 |
DC72964 |
VU0026921
VU0026921 is a small molecule modulator of metal homeostasis in gram-positive pathogens, disrupts metal homeostasis in multiple Gram-positive bacteria, leading to increased reactive oxygen species and cell death. |
301321-65-3 |
DC72965 |
NPP-669
NPP-669 (NPP669) is an orally bioavailable cidofovir (CDV) analogue and prodrug, has increased lipophilicity, improved oral absorption, reduced nephrotoxicity, increased cellular uptake, and increased activity against several dsDNA viruses compared to CDV |
2407828-99-1 |
DC72966 |
AG-7404
AG-7404 (AG7404) is a potent, irreversible inhibitor of picornaviral 3C protease, exhibits EC50 values of 80-674 nM against a large panel of programmatically important poliovirus strains. |
343565-99-1 |
DC72967 |
SJW-2C-227
SJW-2C-227 is a broad-spectrum anti-viral compound that target enterovirus 2C potein, inhibits 2C ATPase activity, exhibits anti-viral activity of SJW-2C-227 with an EC50 of 1.7 µM against EVA71 and 0.52 µM against EV-D68. |
693821-95-3 |
DC72968 |
ZHSI-1
ZHSI-1 is a novel inhibitor of Enterovirus 71 (EV71) and Coxsackie A16 (CVA16) replication, interacts with 3D and potently inhibits EV71-induced cell death with IC50 of 3.27 uM. |
2925912-67-8 |
DC72969 |
ZHSI-1 hydrochloride
ZHSI-1 hydrochloride is a novel inhibitor of Enterovirus 71 (EV71) and Coxsackie A16 (CVA16) replication, interacts with 3D and potently inhibits EV71-induced cell death with IC50 of 3.27 uM. |
|
DC72970 |
Cotransin CT8
Featured
Cotransin CT8 (CT-08) is a substrate-selective co-translational translocation inhibitor, binds the Sec61 translocon to inhibit cotranslational translocation of a subset of secreted and type I transmembrane proteins. |
1000770-96-6 |
DC72971 |
Cotransin CT9
Cotransin CT9 (CT-09) is a substrate-selective co-translational translocation inhibitor, binds the Sec61 translocon to inhibit cotranslational translocation of a subset of secreted and type I transmembrane proteins. |
438239-90-8 |
DC72972 |
PS3061
PS3061 (PS 3061) is a substrate-selective co-translational translocation inhibitor, modulates SEC61 translocon and inhibits both DENV and ZIKV virion production and replication. |
2377739-98-3 |
DC72973 |
CWHM-974
CWHM-974 is a fluphenazine derivative with antifungal activity against Candida albicans, significantly reduces susceptibility to multidrug transporter-mediated resistance. |
|
DC72974 |
FC12406
FC12406 is a highly potent and broadly active antifungal agent, has MIC of 0.2 ug/mL against Candida albicans. |
2891868-69-0 |
DC72975 |
MMV688766
MMV688766 (MMV 688766) is a small molecule displaying broad-spectrum fungicidal activity through perturbation of lipid homeostasis, inhibits the growth of four geographically distinct C. auris clades with MIC80 of 12.5-50 uM. |
904508-14-1 |
DC72976 |
NP-BTA
NP-BTA is a potent, allosteric inhibitor of C. albicans glutaminyl-tRNA synthetase Gln4 with ITC KD of 180 nM and IC50 of 108 nM, strongly inhibits Candida albicans growth. |
544420-99-7 |
DC72977 |
NPD6433
NPD6433 is a novel broad-spectrum antifungal agent with MIC <10 ug/mL against C. albicans, Candida glabrata, Candida auris, and C. neoformans, inhibits Fas1 enoyl reductase activity. |
895908-81-3 |